Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EMvision Medical DevicesASX:EMV +5.62%23 EV-to-OCF is -15.06 as of Aug. 10, 2026. GuruFocus rates ASX:EMV with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 853 Medical Devices & Instruments companies, EMvision Medical Devices ranks better than 84.41% on this metric.
The historical rank and industry rank for EMvision Medical Devices's EV-to-OCF or its related term are showing as below:
ASX:EMV'
s EV-to-OCF Range Over the Past 10 Years
Min: -15.06 Med: 0 Max: -15.06
Current: -15.06
During the past 7 years, the highest EV-to-OCF of EMvision Medical Devices was -15.06. The lowest was -15.06. And the median was .
ASX:EMV's EV-to-OCF is ranked better than 84.41% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.85
vs ASX:EMV: -15.06
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EMvision Medical Devices (ASX:EMV) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EMvision Medical Devices's PE Ratio (TTM) for today is calculated as:
EMvision Medical Devices's share price for today is A$1.69.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EMvision Medical Devices's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.118.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
EMvision Medical Devices EV-to-OCF Related Terms
EMvision Medical Devices EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, EMvision Medical Devices's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EMvision Medical Devices EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, EMvision Medical Devices's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where EMvision Medical Devices's EV-to-OCF falls into.
EMvision Medical Devices's current Enterprise Value is A$134.63 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EMvision Medical Devices's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-8.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMvision Medical Devices (ASX:EMV) has a EV-to-OCF of -15.06 as of Aug. 10, 2026. According to the industry distribution chart, EMvision Medical Devices ranks #133 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 15.6%.
Is EMvision Medical Devices' EV-to-OCF too high?
EMvision Medical Devices' current EV-to-OCF is -15.06. Based on the distribution chart, EMvision Medical Devices ranks #133 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, EMvision Medical Devices has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does EMvision Medical Devices' EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, EMvision Medical Devices ranks #133 out of 853 companies for EV-to-OCF. This places EMvision Medical Devices in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.85, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EMvision Medical Devices's current EV-to-OCF is -15.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EMvision Medical Devices stock overvalued right now?
EMvision Medical Devices (ASX:EMV) has a current EV-to-OCF of -15.06. The current EV-to-OCF is -15.06. EMvision Medical Devices' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For EMvision Medical Devices (ASX:EMV), the current EV-to-OCF is -15.06 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EMvision Medical Devices Ltd is an Australian medical device company. The company is focused on the research and development, and commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. Its focus is portable, cost-effective, and non-invasive brain scanners, including a bedside device (emu) and an ultra-lightweight pre-hospital device (First Responder). Its first indication targets acute stroke care, with a second planned indication in traumatic brain injury.
23GF Score
Get the complete analysis for ASX:EMV
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EMV has been successfully added to your 
